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Abstract 
Background: The repair of urinary bladder tissue is a necessity for tissue loss due to cancer, trauma, or congenital 
abnormalities. Use of intestinal tissue is still the gold standard in the urological clinic, which leads to new problems 
and dysfunctions like mucus production, stone formation, and finally malignancies. Therefore, the use of artificial, 
biologically derived materials is a promising step towards the augmentation of this specialised tissue. The aim of this 
study was to investigate potential bladder wall repair by two collagen scaffold prototypes, OptiMaix 2D and 3D, naïve 
and seeded with autologous vesical cells, as potential bladder wall substitute material in a large animal model.
Methods: Six Göttingen minipigs underwent cystoplastic surgery for tissue biopsy and cell isolation followed by 
implantation of unseeded scaffolds. Six weeks after the first operation, scaffolds seeded with the tissue cultured 
autologous urothelial and detrusor smooth muscle cells were implanted into the bladder together with additional 
unseeded scaffolds for comparison. Cystography and bladder ultrasound were performed to demonstrate structural 
integrity and as leakage test of the implantation sites. Eighteen, 22, and 32 weeks after the first operation, two mini-
pigs respectively were sacrificed and the urinary tract was examined via different (immunohistochemical) staining 
procedures and the usage of two-photon laser scanning microscopy.
Results: Both collagen scaffold prototypes in vivo had good ingrowth capacity into the bladder wall including a 
quick lining with urothelial cells. The ingrowth of detrusor muscle tissue, along with the degradation of the scaffolds, 
could also be observed throughout the study period.
Conclusions: We could show that the investigated collagen scaffolds OptiMaix 2D and 3D are a potential material for 
bladder wall substitution. The material has good biocompatible properties, shows a good cell growth of autologous 
cells in vitro, and a good integration into the present bladder tissue in vivo.
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Background
Numerous tissue engineering strategies have been devel-
oped over recent years in an attempt to generate a uri-
nary bladder wall substitute that would be applicable for 
patients suffering from malfunctions, cancer or trauma 
[1–7]. The experimental investigation of a broad range 
of differing materials for vesical augmentation reflects 
the ongoing challenge for sufficient medical treatment 
concerning malfunctions of the urinary bladder. As the 
bladder is a complex organ, this aim is hard to achieve. 
The storage and voiding functions are regulated by an 
intricate network of different tissues, nerve tracts, trans-
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relative complexity of this tissue, it is not surprising that 
the clinical gold-standard, the usage of absorptive intes-
tinal material, is sub-optimal for long-term treatments, 
and the need for an equivalent bioengineered alternative 
apparent [11].
Non-degrading materials such as polytetrafluorethyl-
ene (Teflon®), silicone or polyurethane were only briefly 
considered as they led to chronic inflammatory reac-
tions, promoted urinary tract infections, calcifications as 
well as fistula formation [12–15]. For this reason, mainly 
biodegradable materials, naturally or artificially derived, 
came into focus within the last years. Processed tissue 
such as bladder acellular matrix grafts (BAMG) or com-
mercially available small intestinal submucosa (SIS) have 
provided a range of different outcomes [4, 6, 15, 16]. Fur-
thermore, SIS was found to induce immune reactions as 
foreign DNA remnants could be detected in the material. 
Moreover, the problem of batch-to-batch variations and 
alterations due to different processing techniques arises 
and can lead to an instable outcome after the implanta-
tion [17–19].
Artificially engineered scaffolds can be designed 
adjusted for desired task and tissue. Furthermore, a mod-
ification with growth factors or the use as drug delivery 
system is viable and can further enhance ingrowth of 
the biomaterial into the host tissue. Especially vascu-
lar endothelial growth factor (VEGF) showed promising 
results in some recent studies but also the graftage with 
recognition patterns for cells like arginine–glycine–
aspartic acid (RGD) or isoleucine–lysine–valine–ala-
nine–valine (IKVAV) is feasible [20–23]. Furthermore, 
the raw materials like polyglycolic acid (PGA), polylactic 
acid (PLA) or polycaprolactone (PCL) are FDA-approved 
and commercially available in adequate amounts [24–26]. 
Drawback of these materials however is that they are for-
eign to the body and are degraded under generation of 
acids, which can enhance rejection of the implant [15]. 
Additionally it has to be granted, that the artificial added 
molecules are not able to promote tumour development 
[6].
The use of extracellular matrix-derived components, 
such as collagen, for scaffold production presents advan-
tages over synthetic polymers and has shown great 
promise in a number of models of tissue engineering for 
regenerative medicine [27–31]. Collagen is degraded by 
enzymes and the degradation products do not interact 
negatively with the surrounding tissue but, because of its 
phylogenetic affinity, can be transformed by the organism 
[6]. In the present study, we selected two differently man-
ufactured collagen type I/III scaffold prototypes, manu-
factured by Matricel  GmbH (Herzogenrath, Germany), 
after an iterative process of several examinations [32–34]. 
The company´s main product, a sponge-like collagen 
scaffold (OptiMaix 3D®), has already been used in differ-
ent approaches of tissue engineering for diverse organs, 
such as esophagus, cartilage, vascular and smooth tis-
sue, with promising outcomes [26–31]. The aim of this 
study was to compare the regenerative potential of col-
lagen scaffolds with a relatively simple, planar or sheet-
like form (i.e. OptiMaix 2D®), with the structurally more 
complex, orientated porous form (OptiMaix 3D) in a 
large animal model. Furthermore, the influence of prior 
cell seeding on scaffold-host integration and bladder tis-
sue repair was also investigated. The employed Göttingen 
minipig race is a small pig, especially bred for experimen-
tal studies. It is widely regarded as an excellent model 
for urological research because the micturition volume 
and voiding frequency closely resemble that of humans 
as we could demonstrate recently. [35]. Here, we present 
our first data about the OptiMaix 2D and 3D, naïve and 
seeded with autologous urothelial (UCs) and detrusor 
smooth muscle cells (SMCs).
Methods
Study design
Six adult female Göttingen minipigs aged 17.8  ±   
1.0  months with an average weight of 44.8  ±  3.9  kg 
(mean ± SD) were obtained from a specific pathogen-free 
(SPF) breeding facility (Ellegaard Göttingen Minipigs A/S, 
Dalmose, Denmark) and clinically examined by a veterinar-
ian after arrival. All animals were acclimatized for at least 
14 days prior to the study.
In a first operation (OPI), two OptiMaix  2D and two 
OptiMaix 3D without cells were implanted into the ven-
tral urinary bladder wall of a Göttingen minipig. The 
excised bladder tissue was used for the isolation and 
tissue culturing of UCs and SMCs (see below). Scaf-
folds were seeded with autologous tissue cultured UCs 
and SMCs after 3  weeks, and remained in an incubator 
for another three weeks prior to the implantation. Dur-
ing operation  II (OPII), one of the implanted OptiMaix 
2D and 3D scaffolds, was excised and substituted by an 
appropriate, freshly prepared naïve 2D or 3D scaffold 
of the same shape. Accordingly, an initial assessment of 
implant–host integration after 6 weeks was possible. 
Additionally, two cell-seeded OptiMaix 2D scaffolds were 
implanted into the right, and one cell-seeded OptiMaix 
3D scaffold was implanted into the left dorsal bladder 
wall (Fig. 1).
At weeks 18, 22 and 32 (i.e. 12, 16 and 26 weeks after 
OPII), two minipigs were sacrificed and the urinary tract 
examined. These time points were chosen due to results 
of two Göttingen minipigs in a preliminary study. The 
degradation of the scaffolds should have been accom-
plished at 14–15 weeks after the implantation, according 
to the assumption of the scaffold’s manufacturer. Instead, 
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pieces of the artificial collagen could still be found. There-
fore, one time point before and one after this first time 
limit, as well as one after a longer period, namely 12, 16 
and 26 weeks after OPII were chosen. In addition, by per-
forming two operations in one animal, more information 
about the timescale of implant-host tissue integration 
could be obtained in accordance with the 3R-principle. 
The study design is presented schematically in Fig. 2.
Surgical procedure
OptiMaix 2D scaffolds were appropriately trimmed to 
fit the custom made, oval Teflon seeding rings (3.3 cm2) 
immediately before implantation. This pre-cut was per-
formed to have a basis for comparison with the seeded 
scaffolds, which were implanted in the second operation. 
The highly porous (pore diameter  ≈100  µm) OptiMaix 
3D scaffolds proved to be fragile and easily damaged, 
thus necessitating the use of a larger surface for suturing. 
The 3D scaffolds were, therefore, implanted and sutured 
in their delivered format of 3 × 4 cm2 (×3.0 mm).
Pre-sedation was performed with an i.m. injection of 
4  mg/kg azaperone (Stresnil®, Sanochemia Pharmazeu-
tika AG, Neufeld, Austria) and 0.1  mg/kg atropine (Dr. 
Franz Köhler Chemie GmbH, Bensheim, Germany). A 
second i.m. injection with 10  mg/kg ketamine (Ceva, 
Düsseldorf, Germany) was administered after 15  min. 
Blood samples were taken from all animals for routine 
blood counts. Anaesthesia was subsequently deepened by 
an i.v. injection of 1 mg/kg propofol (Fresesnius Kabi, Bad 
Homburg, Germany) and the animals were intubated. 
Inhalation anaesthesia was maintained with 1–1.5 vol% 
of isoflurane (Forene®, abbvie, Darmstadt, Germany). 
A continuous infusion of fentanyl (0.02  mg/kg  h, Rotex 
Medica GmbH, Trittau, Germany) was also administered 
to ensure analgesia. Additional volume demand during 
laparotomy was compensated with an infusion of 0.9% 
Fig. 1 Study design. a Isolation and cultivation of primary cells from Göttingen minipig urinary bladder. Seeding of scaffolds was performed after 
3 weeks and implantation of seeded scaffolds into the pig bladder after another 3 weeks. b During OPI two OptiMaix 2D (oval) and 3D (square) each, 
without cells, were implanted into the ventral bladder wall. c During OPII, one of the implanted OptiMaix 2D and 3D each, was excised and sub-
stituted by a fresh unseeded scaffold of the same make and shape. Two autologously seeded OptiMaix 2D scaffolds were implanted into the right 
and one autologously seeded OptiMaix 3D scaffold was implanted in the left dorsal bladder wall. After OPI 15.4% and after OPII 24.7% of the native 
tissue had been substituted by the OptiMaix scaffolds
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sodium chloride solution (B. Braun, Melsungen, Ger-
many) with a rate of 4 ml/kg h.
A midline incision of the lower abdomen was per-
formed after cleaning and disinfection of the operation 
field. The pigs were provided with a transurethral cathe-
ter and the urinary bladder was lifted above the symphy-
sis by filling it with 200 ml 0.9% sodium chloride solution. 
Urothelial and detrusor muscle tissue of the designated 
implantation sites was sharp-dissected with scalpel and 
scissors while simultaneously creating a serosal flap 
(Fig. 3b). The biopsies, which corresponded in size to that 
of the intended implants (i.e. 0.8 × 1.4 cm2 for the ellip-
soid 2D scaffold and 3.0 ×  4.0  cm2 for the 3D scaffold) 
were transferred to a sterile cup containing pre-warmed 
“modified Eagle’s Medium” (MEM, Life Technologies, 
Braunschweig, Germany) and immediately processed 
in the cell culture facility (see below). Collagen scaffolds 
were implanted and secured in the prepared lesion sites 
with resorbable PDS II 4-0 sutures (Johnson & John-
son, Medical GmbH, Norderstedt, Germany, Fig.  3c). 
Non-absorbable marking sutures were set with Prolene 
3-0 (Johnson and Johnson) at four corners of the scaf-
fold (Fig. 3d) using black suture for the 2D scaffold and 
blue for the 3D scaffold. The remaining serosal flap was 
used to cover the scaffold and was fixed with PDS II 4-0 
(Fig.  3e). The bladder was then filled with 0.9% sodium 
chloride solution to check for leakage. The peritoneum, 
muscle, and subcutis were closed separately with Vicryl 
2-0 sutures (Johnson and Johnson) and the skin closed 
with Prolene 2-0 sutures (Johnson and Johnson). A fresh 
transurethral catheter was placed to avoid pressure 
on the healing bladder tissue. Prophylactic antibiotics 
(Cefuroxime 500  mg, Heumann Pharma GmbH & Co., 
Nürnberg, Germany) were given twice daily and Carpro-
fen (Rimadyl®, 4 mg/kg body weight, Pfizer Deutschland 
GmbH, Berlin, Germany) was given once daily for anal-
gesia via oral administration for five days.
Post‑operative care
The health status of the animals was checked every day. 
Assessment of urinary bladder integrity was performed 
via cystography after one week. For this, minipigs were 
sedated as described above and up to 350  ml of radio-
contrast medium (Conray™, Mallinckrodt pharmaceu-
ticals, Dublin, Ireland) was infused into the bladder via 
the transurethral catheter. In case of leakage, a fresh tran-
surethral catheter remained in the bladder until a second 
follow-up after 1 week.
After removal of the catheter, the minipigs were 
observed in a metabolic cage for 24  h with regular diet 
and controlled water ad  libitum. This monitoring was 
also done prior to and after each operation as well as 
the termination of the experiment to evaluate the blad-
der function. Proof of the time point and volume of the 
micturition was ensured by video monitoring (Mobotix, 
Langmeil, Germany) and an urological flow meter con-
sisting of a scale with a collecting vessel and correspond-
ing software (Flow, Laborie, Montreal, Quebec, Canada) 
as described elsewhere [36].
Cell culture of UCs and SMCs
Autologous UCs and SMCs were isolated as described 
previously [37]. Briefly, the urothelium and detrusor 
muscle were dissected from the bladder biopsy and the 
cells mechanically dissociated. After gentle agitation 
(1 h at 37 °C) in MEM with 400 µg/ml collagenase (Lib-
erase®, Roche Applied Sciences, Penzberg, Germany) 
the cell suspension was filtered through a stainless steel 
mesh (1.0 mm2 pore size), washed three times with MEM 
containing 10% (v/v) fetal calf serum (FCS, Thermo Sci-
entific) and transferred in collagen-coated (Biochrom 
AG, Berlin, Germany) cell culture flasks (Nunclon™, 
Thermo Scientific). The UCs were cultured in Keratino-
cyte-SFM (Life Technologies) and SMCs in a selection 
medium described elsewhere in a humidified incubator 
with 5% CO2 at 37  °C [32]. The selection medium was 
used for 3 days to inhibit the growth of fibroblasts in the 
SMC population. For the subsequent cultivation, SMCs 
were treated with smooth muscle cell growth medium 2 
(Promo Cell GmbH, Heidelberg, Germany). The cultured 
cells were regularly monitored via a Leica DMI 4000B 
(Leica Microsystems GmbH, Wetzlar, Germany) and 
integrated software (Diskus 4.80.5909, Hilgers, Technis-
ches Büro, Königswinter, Germany).
Fig. 2 Timeline of the in vivo study. During OPI biopsies were taken for cell cultivation and unseeded scaffolds were implanted. Six weeks later, two 
scaffolds implanted in OPI were excised for histological evaluation and fresh unseeded as well as autologously seeded scaffolds were implanted. 
Termination of the experiment was at 18, 22 and 32 after OPI. Number in brackets gives the quantity of implanted scaffolds
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Cell‑seeding and implantation of OptiMaix scaffolds
OptiMaix 2D scaffolds were fixed in the custom made 
seeding rings and seeded with SMCs. As mentioned 
above, OptiMaix 3D scaffolds could not as planned be 
cut to the size of the seeding ring, and therefore, were 
laid flat in a petri dish and then seeded similarily to 
the OptiMaix 2D. After 4 h, the petri dishes were filled 
with MEM containing 20% FCS and 1% amphotericin B 
and 1% gentamicin. For co-culture, one day later, SMC-
seeded scaffolds were placed in a fresh petri dish and 
UCs were seeded onto the other side of the scaffold. An 
additional scaffold of each type was seeded to serve as a 
control for cell growth. Medium was changed every sec-
ond day.
Histochemical and immunohistochemical staining 
of scaffolds
Two times a week (d1 and d4), a piece of 3 mm width of the 
seeded control scaffolds was cut off and fixed in Carnoy’s 
Solution [60% ethanol (Merck, Darmstadt, Germany), 
30% chloroform, 10% acetic acid (both Carl Roth GmbH 
& Co.KG, Karlsruhe, Germany)] for 4  h. The fixed sam-
ples were dehydrated through ascending concentrations 
of ethanol, paraffin embedded and cut into 3 µm sections. 
For subsequent staining, sections were deparaffinized and 
rehydrated in descending concentrations of ethanol, even-
tually being washed in PBS. Sections were stained with 
haematoxylin–eosin (HE), 4′,6-Diamidin-2-phenylindol 
(DAPI) and nuclear fast red–fast green (RG).
Immunohistochemistry with pancytokeratin (PanCK) 
and α-smooth muscle actin (α-SMA) was performed as 
described previously using the antibodies mentioned 
in Table  1 [37]. Briefly, sections were deparaffinized in 
descending ethanol solutions. The antigen retrieval was 
performed using citrate-buffer (Zytomed System GmbH, 
Berlin, Germany) in a steamer for 30  min, and primary 
antibodies, diluted in PBS, were incubated for 1  h. The 
secondary antibody and chromogen development was 
performed using the DAKO Real EnVision HRP rabbit/
mouse with DAB. Images of the stainings were gener-
ated using a Leica DM6000B with external light source 
for fluorescence excitation Leica EL6000 and integrated 
Fig. 3 Implantation procedure of a seeded OptiMaix 2D into the minipig bladder. a Seeded OptiMaix 2D in the custom made seeding ring. b 
Creation of the serosal flap. c Setting of marks with non-degradable sutures. d Implanted OptiMaix 2D. e Sealed implantation site. Implantation of 
OptiMaix 3D was performed similarily (not shown)
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software (Diskus 4.80.5909, Hilgers, Technisches Büro, 
Königswinter, Germany).
Termination of the experiment
The minipigs were anaesthetized as mentioned above. 
Final examination of bladder integrity, shape, and urinary 
reflux were performed via ultrasound and bladder filling 
with 0.9% sodium chloride solution.
The pigs were then euthanized by i.v. injection of 
0.16  g/kg barbiturate (Narcoren®, Merial, Hallberg-
moos, Germany). The urinary bladder and kidneys with 
ureters were removed and weighed. The urinary bladder 
was fixed for 24  h and kidneys with ureters were fixed 
for seven days in 4% phosphate buffered formaldehyde 
(Merck).
The whole bladder was processed for histological eval-
uation with emphasis on the implantation sites. Three 
sections of the kidney including cortex and medulla, the 
renal pelvis, as well as the proximal and distal ureters 
were examined for signs of pathological alterations. The 
implanted scaffolds were processed in the same man-
ner as the cell-seeded scaffolds (described above). This 
involved sample dehydration, paraffin embedding and 
3  µm sections being prepared. The histochemical stain-
ing of the bladder wall was performed using Elastica van 
Giesson’s staining (EVG) to provide an overview of the 
general morphology of the implantation site. PanCK was 
used to identify the urothelial layer, α-SMA was used for 
control of the detrusor muscle structure, cluster of dif-
ferentiation 34 (CD34) and VEGF to identify blood ves-
sels for vascularization and S100 as an indirect indicator 
of nerve fibre distribution (antibodies see Table  1). All 
staining methods were performed as mentioned above.
Two‑photon laser scanning microscopy (TPLSM)
In an attempt to evaluate the extent of implanted scaf-
fold degradation, unstained sections were examined 
using a two-photon microscope (FV1000MPE, Olympus 
Corp., Tokyo, Japan) attached to a pulsed Ti–Sapphire 
laser (MaiTai DeepSee, SpectraPhysics) with a 25× water 
immersion objective (1.05NA, WD2.0). For excita-
tion of the collagen remnants inside the tissue, the laser 
was tuned to the wavelength of 750  nm. The emission 
autofluorescent signals were collected with bandpass fil-
ters at 419–465, 495–540 and 590–650 nm, respectively. 
The intense autofluorescent structure of the scaffold 
was mainly detected in the range of 419–465 and 495–
540 nm. Further image processing was performed using 
ImageJ (Version 1.49j10, National Institutes of Health, 
USA).
Statistics
Data analysis of micturition volumes was performed 
using Origin (9.1 OG, 1991–2013 Origin Lab Corpo-
ration, Northampton, USA). All results are shown as 
mean  ±  SD. All examined data was tested for normal 
distribution by the Shapiro-Wilks test. Statistical differ-
ences were determined via One-way ANOVA with Tukey 




Cell isolation resulted in differing cell cultivation counts 
based on intraindividual conditions of the animals. Nev-
ertheless, all isolations were successful and a an average 
cell yield of 4.5  ×  106 UCs and 2.9  ×  107 SMCs could 
be seeded onto the scaffolds resulting in a distribution 
of 2.4 ×  105 (UCs) and 1.6 ×  106 (SMCs) per cm2. The 
SMCs were building a multilayer on top of the structured 
side of the OptiMaix 2D as the fibres of the scaffold were 
deflating when in contact with the cell culture medium 
(Fig. 4a). After 3 days, a closed layer of UCs was visible on 
the dense side of the OptiMaix 2D scaffold. After 2 weeks 
in culture, layers up to three cells thick could be observed 
in histological sections (Fig. 4b). The OptiMaix 3D scaf-
fold allowed both UCs and SMCs to penetrate, adhere 
and grow inside the longitudinally orientated micro-
pores of the 3D scaffold. Since these micro-pores had an 
average diameter of 100 µm, cells usually appeared to be 
associated with the walls of the porous framework rather 
than filling the pores.
Surgery
The scaffold material of OptiMaix 2D had an appearance 
and texture similar to wet chamois and could, therefore, 
Table 1 Antibodies for immunohistochemical staining of control scaffolds and excised bladder biopsies
Antibody Clone number Dilution Company
α-Smooth muscle actin 1A4 1:400 Dako GmbH, Hamburg, Germany
PanCK AE1/AE3 1:300 Dako GmbH, Hamburg, Germany
CD34 QBEnd-10 1:200 Antibodies-Online GmbH, Aachen, Germany
VEGF VG76e 1:200 Antibodies-Online GmbH, Aachen, Germany
S100 Z0311 1:1000 Dako GmbH, Hamburg, Germany
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be easily sutured into the urinary bladder wall. In con-
trast, the OptiMaix 3D, was more delicate because of its 
highly porous structure. Preliminary attempts to suture 
the 3D scaffold in the same precut oval shape as the 
2D failed due to rupturing of the scaffold at the suture 
points. This technical difficulty was overcome by using 
the whole 3 × 4 cm2 scaffolds that could be successfully 
sutured into the wall of the bladder. Instead of three small 
scaffolds, now only two original-sized 3D scaffolds were 
implanted.
All six animals recovered well after surgery and the 
analysis of blood parameters showed no signs of inflam-
mation or infection. As a reaction to the blood loss that 
occurred during the operations, the number of thrombo-
cytes had increased and haemoglobin and haematocrit 
values had decreased. These values returned to normal 
levels by the end of the experiment (Table 2). Although 
there was a tendency for reduced micturition volume 
at 6 weeks (the time point of OPII) there was no statis-
tically significant reduction of volumes at any survival 
time studied (Fig. 5). There were no signs of incontinence 
or infections of the urinary tract. Cystography revealed 
that the implantation sites of the OptiMaix 3D scaffolds 
had a greater potential for leakages than the 2D scaf-
folds which occurred in two of the six pigs. The bladder 
shape was influenced by the multiple implants leading to 
slightly pear-shaped urinary bladders. However, by the 
end of the experiment, the bladder demonstrated a nor-
mal shape (Fig. 6). There was no urinary reflux to the kid-
neys. Before each operation and at the termination of the 
experiment, only ultrasound was performed, since the 
contrast agent lead to oedema in the bladder urothelium.
Histological evaluation
The serosa mainly was a homogenous closed layer, solely, 
the usage of different coloured non-degradable marking 
sutures allowed a macroscopic differentiation of Opti-
Maix 2D and 3D scffolds. However, the marking sutures 
favoured adhesion of the bladder serosa to the omen-
tum and surrounding organs and had to be carefully 
dissected during the removal of the urinary tract at the 
end of the experiment. Bladder weight was in the range 
of 89.5 ±  16.2  g, the left kidney had an average weight 
of 105.5 ± 22.2 g and the right kidney of 108.5 ± 26.8 g. 
After 32  weeks, the implantation sites were still visible 
on the interior surface. No macroscopic anomalies of 
the urinary tract were visible. Kidneys and ureters were 
without any pathological alteration, no kidney reflux 
occurred and the bladder was without calcifications or 
stone formation.
At week six, the scaffold structure seemed nearly 
intact but the degradation process had already started. 
Fig. 4 OptiMaix 2D and 3D seeded with (a) SMCs and (b) UCs before implantation. SMCs are building a multilayer on top of the fibres of the struc-
tured side of OptiMaix 2D (arrows) but are migrating inside the open pores of OptiMaix 3D. UCs are lining the dense side of OptiMaix 2D (arrows). 
Due to the open structure of OptiMaix 3D, UCs are also infiltrating the scaffold. Scale bar = 50 µm
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Remnants of the OptiMaix 2D were still visible after 
32 weeks. Figures 7 and 8 show this process, as the for-
eign collagen appears dark violet in the EVG stain-
ing. However at this time, a closed urothelial layer with 
underlying connective tissue was clearly visible on the 
inner surface of the OptiMaix 2D scaffold. The seeding of 
urothelial cells on the collagen scaffold here did not seem 
to have any influence on this process. The detrusor mus-
cle grew from the sides of the implant towards its centre. 
Here, the dense structure decelerated the ingrowth of the 
adjacent tissue into the scaffold. Furthermore, pre-seed-
ing with SMCs did not improve the ingrowth process. 
Nevertheless, until 32  weeks, muscle tissue was grow-
ing. The staining with CD34 and VEGF showed enhanced 
vascularization with blood vessels growing through the 
scaffold material at six and 18  weeks. This vasculariza-
tion seemed to become less with 22 weeks and was at a 
normal level compared to the native control when the 
Table 2 Blood and renal parameters of Göttingen minipigs
All results are shown as mean ± SD
No significant differences could be examined
OP I After OP I OP II After OP II Termination Norm
Kidney values (serum) 0 weeks 2 weeks 6 weeks 8 weeks 18/22/32 weeks
Total protein (g/dl) 6.4 ± 0.7 5.2 ± 0.5 6.7 ± 0.5 6.1 ± 0.3 6.5 ± 0.7 4.5–8.5
Urea (mmol/l) 2.4. ± 1.1 1.8 ± 0.1 2.2 ± 0.9 3.7 ± 3.7 2.2 ± 0.9 3.3–8.3
Creatinine (µmol/l) 107.5 ± 13,8 78.4 ± 16.7 119.3 ± 20.8 127.8 ± 73.6 107.7 ± 19.5 40–133
Uric acid (µmol/l) 14.0 ± 0.7 13.8 ± 0.8 13.5 ± 0.8 14.5 ± 1.8 14.0 ± 0 –
Sodium (mmol/l) 143.8 ± 1.7 141.2 ± 1.3 141.7 ± 8.3 144.0 ± 1.7 142.5 ± 2.7 140–160
Potassium (mmol/l) 3.7 ± 0.3 3.7 ± 0.4 3.6 ± 0.7 3.9 ± 0.5 3.7 ± 0.3 4.0–5.0
Chloride (mmol/l) 101.5 ± 2.1 99.0 ± 1.4 100.0 ± 0.9 99.0 ± 2.4 101.5 ± 0.6 102–106
Blood count
Leucocytes (×103/µl) 7.2 ± 1.6 7.5 ± 2.1 7.6 ± 4.7 11.9 ± 6.7 7.5 ± 4.0 7.0–22.0
Erythrocytes (×106/µl) 5.8 ± 0.7 5.0 ± 0.9 ↓ 7.1 ± 2.3 4.5 ± 1.1 ↓ 5.5 ± 0.9 5.8–8.0
Thrombocytes (×103/µl) 507.7 ± 93.1 699.0 ± 179.9 ↑ 371.7 ± 171.3 819.3 ± 236.8 ↑ 554.0 ± 142.0 175–587
Haemoglobin (g/dl) 11.6 ± 1.1 10.5 ± 1.7 14.2 ± 4.1 9.2 ± 1.9 ↓ 11.1 ± 0.9 10.0–16.0
Haematocrit (%) 32.2 ± 2.3 29.1 ± 4.2 ↓ 39.0 ± 10.9 25.8 ± 5.3 ↓ 30.9 ± 2.5 33.0–45.0
MCV (fl) 56.0 ± 6.1 58.3 ± 4.7 56.2 ± 6.1 57.8 ± 6.1 56.8 ± 5.6 50.0–68.0
MCH (pg) 20.2 ± 2.2 20.9 ± 1.8 20.5 ± 2.3 20.5 ± 2.3 20.4 ± 2.2 17.0–21.0
MCHC (g/dl) 36.2 ± 0.9 35.9 ± 1.0 36.4 ± 0.6 35.5 ± 0.7 36.0 ± 0.6 30.0–35.0
Differential blood count
Unsegmented granulocytes (%) 5.0 ± 1.9 5.8 ± 1.9 5.8 ± 3.1 5.3 ± 2.2 5.2 ± 3.6 0–7
Segmented granulocytes (%) 31.5 ± 16.4 33.4 ± 11.4 33.7 ± 14.3 36.2 ± 12.5 26.5 ± 18.5 10–39
Lymphocytes (%) 54,5 ± 17,6 51.2 ± 10.1 54.2 ± 15.1 43.8 ± 22.7 60.5 ± 24.7 49–85
Monocytes (%) 8.0 ± 3.5 7.6 ± 2.3 5.5 ± 1.4 7.0 ± 2.6 6.7 ± 2.7 0–5
Eosinophils (%) 0.7 ± 1.0 1.8 ± 0.8 0.7 ± 0.8 0.7 ± 1.0 1.0 ± 0.9 0–6
Basophils (%) 0.3 ± 0.5 0.2 ± 0.4 0.2 ± 0.4 0.3 ± 0.5 0.2 ± 0.4 0–2
Fig. 5 Micturition volume of six Göttingen minipigs at different 
stages of the experiment. The minipigs were monitored in a meta-
bolic cage for 24 h with camera and flowmeter before each operation 
and after removal of the transurethral catheter. No significant differ-
ences in micturition volume could be detected between the different 
stages of the study
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tissue had reorganized itself at 32 weeks. The S100 stain-
ing showed a continuous ingrowth of nerve fibres into 
the new tissue.
OptiMaix 3D remnants could also be found after 
32 weeks (Figs. 9, 10). Compared to the dense structure of 
the 2D scaffold, after 6 weeks, adjacent connective tissue 
had grown inside the wide pores of the sponge-like struc-
ture. Seeding with cells in this case also did not acceler-
ate this process, but quite the contrary; the seeded 3D 
scaffolds seemed to be encapsulated by the surrounding 
tissue in both pigs at 18 weeks. This phenomenon could 
not be found in the four pigs housed for 22 and 32 weeks. 
Here, remnants of the scaffold could favourably be found 
beneath the urothelium and less in the muscle regenera-
tion zone. As anticipated, the pore structure of the Opti-
Maix 3D was a disadvantage concerning the urothelium. 
The urothelial cells, like in vitro, lined the inside of these 
pores and were not able to build a closed layer on top of 
the scaffolds. Instead, scattered urothelial clusters had 
formed inside the scaffold by 6 weeks. This phenomenon 
was increasing until 18 weeks and abated after 22 weeks. 
At 32  weeks, the urothelium on top of the scaffold had 
reorganized in association with ongoing scaffold-degra-
dation, and could clearly be seen as a single, continuous 
band of cells. Vascularization and nerve-fibre ingrowth 
were comparable to the OptiMaix 2D scaffold.
TPLSM confirmed the general histological and immu-
nohistochemical observations concerning the degrada-
tion of the OptiMaix scaffolds. Remnants could be mainly 
found in the occlusion zone in the periphery of the 
implantation sites (Fig. 11). The ingrowth of adjacent tis-
sue into the OptiMaix 2D was clearly less prominent than 
in the OptiMaix 3D. Yet again, no difference between 
seeded and unseeded scaffolds could be detected.
Discussion
The aim of this study was the comparison of two differ-
ently manufactured collagen scaffolds OptiMaix as mate-
rial for bladder wall repair. In this context, the building 
of a (multi-)layer of cells on both scaffolds with a subse-
quent good cell growth in vitro speaks for a high biocom-
patibility. The dense side of the OptiMaix 2D reached 
a desirable result for the UCs, whereas, the SMCs were 
only growing on the surface of the scaffold instead of 
growing in. The OptiMaix 3D in contrast, allowed migra-
tion of cells into the scaffold structure, which is not 
desirable for the UCs. Another issue arising with the 
OptiMaix  3D was the difficult sewing process during 
the operations. Regarding this aspect, the OptiMaix  2D 
was relatively easier to handle and additionally one week 
after operation, the implantation sites of the 2D scaffolds 
were closed. Indicated by cystographies, the implanta-
tion sites of the 3D scaffolds needed longer recovery; 
hence, the pigs were in need of a transurethral catheter 
for an extended period. These differences in permeabil-
ity coincide with the findings of Montzka et al. [32] who 
performed experiments with these scaffolds in an Ussing 
chamber.
Six pigs with big inter-individual micturition differences 
were used in our study. Although there were differences 
Fig. 6 Ultrasound and cystography of Göttingen minipigs. Cystography was performed post-OP after removal of the transurethral catheter for 
evaluation of bladder shape and integrity. As the contrast agent lead to oedema, immediately before operations and the termination of the experi-
ment only ultrasound was performed. Filling was performed with 300 ml sodium chloride (0.9%) and contrast agent respectively
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Fig. 7 Histological development of implanted unseeded OptiMaix 2D scaffolds. Six weeks after implantation, the scaffold structure is still dense, but 
degradation has already started and is proceeding until 32 weeks. Connective tissue is forming on top of the scaffold (EVG) and is lined by newly 
built urothelium (PanCK). Blood vessels are growing into the artificial collagen (CD34, VEGF) and nerve fibres (S100), which go together with the 
ingrowth of adjacent muscle tissue (α-SMA). S scaffold, M muscle, CT connective tissue. Scale bar = 50 µm
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Fig. 8 Histological development of implanted seeded OptiMaix 2D scaffolds. Eighteen weeks after implantation, like in the unseeded scaffold, still 
dense regions of scaffold tissue can be found (EVG), but are already degrading and are broken up by the surrounding tissue and infiltrated by blood 
vessels (CD34, VEGF). Building of an urothelial layer and connective tissue can also be noticed (EVG, PanCK). Muscle tissue together with nerve 
fibres is growing in from the adjacent tissue (S100, α-SMA). Overall, the development of the implantation sites until 32 weeks is comparable to the 
unseeded OptiMaix 2D scaffolds. S scaffold, M muscle, CT connective tissue. Scale bar = 50 µm
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Fig. 9 Histological development of implanted unseeded OptiMaix 3D scaffolds. Six weeks after implantation, the scaffold seems to be still intact. 
Connective tissue has started to grow inside the open pores (EVG) and also the ingrowth of muscle tissue is occurring (α-SMA). The urothelium has 
closed the luminal side of the scaffold but is growing scattered and building vesicles inside the pores (PanCK). These processes are advancing until 
week 32 with building of a more structured bladder wall and a smoother urothelium. Blood vessels (CD34, VEGF) and nerve fibres (S100) too, are 
evolving during this time span. S scaffold, M muscle, CT connective tissue. Scale bar = 50 µm
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Fig. 11 TPLSM—autofluorescence of unseeded (above) and seeded (below) OptiMaix scaffolds. After 6 weeks, 2D still appears compact but is 
degrading and infiltrated by the adjacent bladder tissue. The 3D scaffold enhances the ingrowth of connective and muscle tissue due to its sponge-
like structure. After 32 weeks, large pieces of both OptiMaix scaffold types are still detectable in the peripheral regions on the luminal side of the 
implantation sites. Scale bar = 100 µm
(See figure on previous page.) 
Fig. 10 Histological development of implanted seeded OptiMaix 3D scaffolds. Similar to the unseeded OptiMaix 3D, the degradation has started 
after 6 weeks, but large pieces of the scaffold can still be found. At 18 weeks, parts of the scaffold structure are encapsulated by fibrotic tissue 
(α-SMA), which might be due to the protein component of the cell culture medium. This phenomenon cannot be found at later time points. As in 
the unseeded scaffolds, the urothelium is closed at 18 weeks and gradually building a smooth layer like in the native tissue. Overall, no differences 
can be found between the building of a new urothelial lining (PanCK), the degradation of the scaffolds (EVG), blood vessels (CD34, VEGF) or nerve 
fibre ingrowth (S100) compared to the unseeded scaffold. S scaffold, M muscle, CT connective tissue. Scale bar = 50 µm
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between the micturition volumes before and after the 
operations, these were not significant and at the end point 
of the experiment all animals had regained normal blad-
der function. Furthermore, we had no indications for 
reflux, incontinence or graft failure which are common 
problems in urinary tissue engineering studies [19, 38].
The flexibility of the OptiMaix 3D allowed a temporary 
dilatation of the bladder wall before the recovery pro-
cess had started and the ingrowing tissue stabilized the 
implantation sites. As this is the first time that these scaf-
folds are tested in vivo for urinary bladder augmentation, 
this is a critical outcome.
We did not find any significant indications that seed-
ing with autologous bladder cells had improved ingrowth 
into the bladder wall. Here, the small size of the scaffolds 
together with the sealing with serosa might have pro-
moted the ingrowth of urothelium and detrusor muscle 
from the adjacent tissue resulting in a greater impact on 
the outcome than the seeding with cells. Additionally, 
the seeded 3D scaffolds, contrary to the unseeded, were 
encapsulated by fibrotic tissue at 6 weeks. This might be 
due to the fact that the cell-scaffold hybrids were incu-
bated in cell culture medium containing FCS. The seeded 
2D scaffolds did not show any signs of encapsulation 
which might be due to the smaller overall surface that 
also reduces the possibility for foreign proteins to adhere 
[39]. Also, the degradation of both scaffolds was not 
accelerated when seeded with autologous cells.
The vascularization process seemed elevated for the 
OptiMaix 2D scaffolds compared to 3D. Already after 6 
weeks, first blood vessels had formed within the compact 
material. No inflammation response regarding the scaffolds 
occurred, which permits the conclusion of a good biocom-
patibility in vivo. This is further supported by the absence 
of stone- or biofilm-formation. Overall, the bladder func-
tion after the implantation was physiologic and even as 25% 
of the bladders are augmented. Not to mention, the blad-
der is withstanding the pressure and the scaffold implants 
whatsoever, are participating in the bladder function.
By TPLSM, it was clearly visible that after six weeks the 
OptiMaix 3D was much more fragmented compared to 
the 2D. The degradation process, for both scaffolds, was 
not completed at 26  weeks. Especially in the fringe of 
the implantation site, remnants of the scaffolds could be 
detected, notably beneath the urothelium.
We are very well aware of the limitations of our study. 
A future approach should entail a partial cystectomy and 
therefore, the fabrication of a larger prototype is defi-
nitely necessary. Also, as we were already proposing in 
our in  vitro study [37], a combination of both scaffolds 
could be advantageous and provide a more convenient 
support for both cell types in vitro and in vivo and lead to 
a more stable implantation site.
In this study, we only used healthy pigs and therefore 
cannot make a statement about the ingrowth of the mate-
rial into morbid tissue. Similarly, the behaviour of urothe-
lial cells isolated from a diseased bladder is impaired, 
which has to be taken into consideration [6, 40]. The next 
logical step would be the use of animals with a diseased 
bladder, e.g. idiopathic detrusor over activity or bladder 
exstrophy [19, 41, 42].
Conclusions
With this study, we were able to show that the OptiMaix 
scaffolds are very promising for bladder wall augmenta-
tion. On the one hand, OptiMaix 2D seems more favour-
able compared to its 3D counterpart regarding handling, 
easier implantation, a quicker tightness of the bladder, 
and better reaction of the surrounding tissue. On the 
other hand, the ingrowth of cells and tissue into the 3D is 
facilitated and a combination of both scaffold types could 
be promising. Nevertheless, the usage for bigger defects 
might include the necessity for seeding with cells, which 
has to be evaluated in future studies.
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